Veracyte, Inc. announced today that it will report its second quarter 2018 financial results after the close of market on Monday, July 23, 2018.
| Veracyte Second Quarter 2018 Conference Call, July 23, 2018 at 4:30 p.m. ET | ||
| Website: | ||
| Dial-in number (U.S.): | (855) 541-0980 | |
| International number: | (970) 315-0440 | |
| Conference ID: | 7784825 | |
The webcast replay will be available on the company’s website approximately two hours following completion of the call and archived on the company’s website.
About Veracyte
Veracyte, Inc. (Nasdaq: VCYT) is a leading genomic diagnostics company that is providing trustworthy and actionable answers that fundamentally improve patient care when current diagnostic tests are uncertain. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary. Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).
Veracyte, Afirma, Percepta, Envisia, the Veracyte logo, and the Afirma logo are trademarks of Veracyte, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180709005684/en/
Contacts
Veracyte, Inc.
Media:
Tracy Morris, 650-380-4413
tracy.morris@veracyte.com
or
Investors:
Keith Kennedy, 650-243-6357
Chief Financial Officer
keith@veracyte.com
